Farjam Goudarzi

Farjam Goudarzi

Auto-generated profile, based on publicly available information

Farjam Goudarzi

Regenerative Medicine Research Center, Kermanshah University of Medical Sciences

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2018 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
FGFarjam Goudarzi
Farjam Goudarzi
AMAdel Mohammadalipour
Adel Mohammadalipour
IKIraj Khodadadi
Iraj Khodadadi
SKSheno Karimi
Sheno Karimi
RMRezvan Mostoli
Rezvan Mostoli
MGMohammad Taghi Goodarzi
Mohammad Taghi Goodarzi

30 May 2017 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
MBMajid Bahabadi
Majid Bahabadi
AMAdel Mohammadalipour
Adel Mohammadalipour
JKJamshid Karimi
Jamshid Karimi
NSNasrin Sheikh
Nasrin Sheikh
GSGhasem Solgi
Ghasem Solgi
IKIraj Khodadadi
Iraj Khodadadi
Context: The active ingredients of traditional medical herbs have been the focus of scientific interests. Objective: This study was designed to explore the mechanisms of actions of parthenolide on nonalcoholic fatty liver disease (NAFLD). Materials and methods: Thirty-five male Wistar rats were fed high-fat diet (HFD) for eight weeks with or without an intraperitoneal injection of parthenolide to develop NAFLD. Liver triacylglycerol (TG), total antioxidant capacity (TAC), total oxidative status (TOS), thiobarbituric acid reactant substances (TBARs), total thiol groups and tumor necrosis factor alpha (TNF-α) and cytochrome P4502E1 (CYP2E1) levels as well as liver ALT, AST and catalase activities were determined. In addition, quantitative real-time PCR was performed to obtain hepatic gene expression levels of TNF-α, CYP2E1 and nuclear factor-κB (NF-κB). Results: HFD caused a significant weight gain and increased liver TG content as well as alteration in ALT and AST activities, which were attenuated after administration of parthenoide (p < .05). Weakened liver antioxidant system (TAC, total thiol groups and catalase activity) and increased oxidative stress markers (TBARs and TOS) were mainly ameliorated by parthenolide treatment (p < .05). Increased hepatic TNF-α, NF-κB and CYP2E1 at the both gene expression and protein levels were found associated with necroinflammatory changes in histopathological observations and were abrogated almost completely after parthenolide treatment. Oxidative and inflammatory changes observed in HFD fed rats were indicative of NAFLD, which were suppressed with parthenolide treatment. Conclusions: Based on these results, parthenolide might be a candidate agent for preventing NAFLD due to its anti-inflammatory and anti-oxidative potency.

22 May 2018 in Free Radical Research
Verified
Journal Article
Closed access
FGFarjam Goudarzi
Farjam Goudarzi
AMAdel Mohammadalipour
Adel Mohammadalipour
MBMajid Bahabadi
Majid Bahabadi
MGMohammad Taghi Goodarzi
Mohammad Taghi Goodarzi
ASArash Sarveazad
Arash Sarveazad
IKIraj Khodadadi
Iraj Khodadadi
Common protocols for chondrogenic differentiation of adipose-derived mesenchymal stem cells (ADSCs) are generally expensive and time-consuming and, so far, have not successfully recreated pure chondrocytes. We hypothesise that a low level of H2O2 may induce differentiation of ADSCs into chondrocytes in a shorter incubation time and relatively lower cost. Therefore, this study aimed to comparatively investigate the effectiveness of H2O2-containing or free medium in the induction of ADSCs to chondrocytes. ADSCs were isolated from the lipoaspirate of four healthy females and evaluated by immunophenotyping for their CD90, CD73, CD44, CD34, and CD45 cell surface markers. Chondrogenic differentiation was carried out using differentiation medium in the presence or absence of 10 and 50 µM H2O2 in normal and three-dimensional culture system. The intracellular contents of reactive oxygen species (ROS) were detected by flow cytometry and fluorescence microscopy. The hydroxyproline, was assessed as marker of collagen and the glycosaminoglycans (GAGs) content was both qualitatively detected and quantitatively determined. Real-time PCR was performed to determine the gene expression level of aggrecan (ACAN), type-II collagen, and transcription factor Sox9. H2O2-treated cells showed pre-chondrocyte morphology on day 1 and chondrocyte pellets were formed on day 14. H2O2-treated cells induced greater pellet sizes and showed significantly higher content of GAGs and hydroxyproline level compared with untreated cells. The gene expression levels of ACAN, collagen type-II, and Sox9 were markedly upregulated by H2O2. Our findings showed for the first time that H2O2-containing differentiation medium is potentially more effective than H2O2-free differentiation medium in the induction of chondrogensis of ADSCs.

2 September 2018 in Drug and Chemical Toxicology
Verified
Journal Article
Closed access
JKJamshid Karimi
Jamshid Karimi
AMAdel Mohammadalipour
Adel Mohammadalipour
NSNasrin Sheikh
Nasrin Sheikh
IKIraj Khodadadi
Iraj Khodadadi
MHMohammad Hashemnia
Mohammad Hashemnia
KHKeshvad Hedayatyanfard
Keshvad Hedayatyanfard
Tyrosine kinase inhibitors (TKIs) have been developed as therapeutic compounds for inhibiting the progression of liver fibrosis. In the present study, the simultaneous treatment of Nilotinib (TKIs) and Losartan was studied. Forty rats were divided into eight groups of fibrosis induced by carbon tetrachloride (CCl4) and therapeutics (Nilotinib, Losartan, and combination therapy). In the end, serum parameters of the liver and gene expression analysis of transforming growth factor-β1, its receptors (TβRII), platelet-derived growth factor, its receptors (PDGFRβ), matrix metalloproteinases (MMP-2 and MMP-9), tumor necrosis factor-α, cytochrome P450 2E1, and collagen1 type 1 were performed. The oxidant/antioxidant factors were also analyzed. Histopathology analysis along with α-SMA immunohistochemistry and hydroxyproline evaluation was also conducted for a more in-depth study. The overall results indicated a better therapeutic effect of co-treatment of Nilotinib–Losartan in comparison with the treatment of each of them alone. Interestingly, some gene and protein factors and fibrotic indices were reduced even to the normal levels of the control group. The results of this study suggest that co-administration of these two combinations, strengthens their anti-fibrotic properties and, due to the routine use of these compounds against AML and blood pressure, these compounds can be used with caution against human liver fibrosis.

9 August 2019 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
AMAdel Mohammadalipour
Adel Mohammadalipour
MHMohammad Hashemnia
Mohammad Hashemnia
FGFarjam Goudarzi
Farjam Goudarzi
ARAlireza Pouyandeh Ravan
Alireza Pouyandeh Ravan

9 August 2022 in Archives of Public Health
Verified
Journal Article
Open access
PDF file
SKSheno Karimi
Sheno Karimi
YPYahya Pasdar
Yahya Pasdar
BHBehrooz Hamzeh
Behrooz Hamzeh
AAAzad Ayenehpour
Azad Ayenehpour
FHFatemeh Heydarpour
Fatemeh Heydarpour
FGFarjam Goudarzi
Farjam Goudarzi
Background: This study was evaluated the association between obesity phenotypes and risk of lower torso musculoskeletal disorders including low back pain (LBP), low back stiffness (LBS), arthralgia, and joint stiffness in Ravansar non-communicable diseases (RaNCD) cohort study. Methods: In this cross-sectional study, 6940 adults were examined for the presence of lower torso musculoskeletal disorders by a physician. Obesity phenotypes including metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) were defined based on the International Diabetes Federation, as well as, body mass index > 30 kg/m2. Metabolically unhealthy non-obesity (MUNO) phenotype was considered as unhealthy metabolic without obesity. Results: The prevalence of LBP, LBS, arthralgia, and joint stiffness in MHO, MUO, and MUNO were significantly higher than in healthy participants compared to obesity phenotypes. Logistic regression showed that MHO phenotype was significantly increased with risk of LBP (OR: 1.19, CI 95%: 1.01–1.41), LBS (OR: 1.44, CI 95%: 1.12–1.86), arthralgia (OR: 1.54, CI 95%: 1.33–1.78), and joint stiffness (OR: 1.84, CI 95%: 1.35–2.52). Moreover, MUO phenotype was positively associated with risk of LBS (OR: 1.46, CI 95%: 1.09–1.94) and arthralgia (OR: 1.66, CI 95%: 1.41–1.96). In addition, MUNO phenotype was associated with a higher risk of arthralgia (OR: 1.21, CI 95%: 1.06–1.37). Conclusion: All three phenotypes, MHO, MUO and MUNO were significantly increased the risk of arthralgia. However, MHO phenotype was significantly associated with a higher risk of all examined lower torso musculoskeletal disorders in the current study.